This trial compares the effect of adding a drug to a radioactive medication to shrink or slow tumor growth in metastatic neuroendocrine tumors.
- Metastatic Neuroendocrine Tumors
1 Primary · 1 Secondary · Reporting Duration: Up to 5 years
Awards & Highlights
2 Treatment Groups
Group I (lutetium Lu 177 dotatate)
1 of 2
Group II (lutetium Lu 177 dotatate, triapine)
1 of 2
94 Total Participants · 2 Treatment Groups
Primary Treatment: Group II (lutetium Lu 177 dotatate, triapine) · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there any vacancies left in this research project?
"Clinicaltrials.gov reveals that this medical trial is currently open for enrollment, with the initial posting taking place on March 15th 2023 and its most recent update occurring a mere fortnight ago." - Anonymous Online Contributor
What is the current size of this research trial's participant pool?
"That is correct. According to clinicaltrials.gov, this medical trial opened on March 15th of 2021 and was recently updated on the 28th of that same month. Researchers are searching for 94 volunteers from a single site." - Anonymous Online Contributor
Has Group II (lutetium Lu 177 dotatate, triapine) been given the go-ahead by federal regulators?
"Our team at Power has assigned a score of 2 to Group II (lutetium Lu 177 dotatate, triapine) due to the fact that there is some safety data available from Phase 2 trials but no evidence yet demonstrating its efficacy." - Anonymous Online Contributor